

Original Article**Current Status of Diagnosis And Treatment of Primary Breast Cancer in Beijing, 2008**

Xiao-mei Yuan^{1*}, Ning Wang^{2*}, Tao Ouyang³, Lei Yang², Ming-yang Song¹, Ben-yao Lin³, Yun-tao Xie³, Jin-feng Li³, Kai-feng Pan¹, Wei-cheng You¹, Lian Zhang^{1**}

Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), ¹Department of Cancer Epidemiology, ²Beijing Cancer Registry, ³Breast Cancer Center, Peking University School of Oncology, Beijing Cancer Hospital & Institute, Beijing 100142, China

DOI: 10.1007/s11670-011-0038-y

© Chinese Anti-Cancer Association and Springer-Verlag Berlin Heidelberg 2011

ABSTRACT

Objective: To investigate the status of diagnosis and treatment of primary breast cancer in Beijing, 2008.

Methods: All the patients who were diagnosed as primary breast cancer in Beijing in 2008 were enrolled in this study. Information of these patients, including the features of tumors, clinical diagnosis and treatment was collected, and filled in the well-designed questionnaire forms by trained surveyors. The missing data were partly complemented through telephone interviews.

Results: A total of 3473 Beijing citizens were diagnosed as primary breast cancer (25 patients with synchronous bilateral breast cancer) in Beijing, 2008. Of them 82.09% were symptomatic. 19.02% and 34.11% were diagnosed using fine needle aspiration biopsy (FNAB) and core needle biopsy (CNB), respectively. 15.92% received sentinel lymph node biopsy (SLNB) and 24.27% received breast conserving surgery (BCS). Among 476 cases with Her-2 positive, only 96 received anti-Her-2 therapy. We found that the standardization level varied in hospitals of different grades, with higher level in Grade-III hospitals. Of note, some breast cancer patients received non-standard primary tumor therapy: 65.63% of the patients with ductal carcinoma in situ (DCIS) received axillary lymph node dissection and 36.88% received chemotherapy; 25.89% of the patients underwent breast conserving surgery without margin status; 12.10% of the patients received chemotherapy less than 4 cycles.

Conclusion: Although most breast cancer patients received basic medical care, the mode of diagnosis and treatment should be improved and should be standardized in the future in Beijing.

Key words: Breast cancer; Diagnosis; Treatment; Nonstandard treatment

INTRODUCTION

Despite a recent decline in breast cancer mortality in the US, breast cancer is still the second leading incidence cancer in women in the world^[1]. The annual age-standardized (world population) incidence rate of breast cancer was 37.8 per 100,000 in Beijing, 2007, with an annual 4.97% increasing from 1998 to 2007 according to the data from Beijing Cancer Registry.

A number of factors have been associated with the outcomes of the breast cancer. The most effective strategies are primary and secondary prevention. In addition, evidence-based standard diagnosis and treatment are critical for survival of breast cancer. Although evidence-based guidelines, such as NCCN and St Gallen consensus^[2,3] have been adopted in most developed countries, little is

known about the current status of diagnosis and treatment of breast cancer in China.

With a population over 1.7 million, Beijing is one of the largest cities in the world. There are over 110 hospitals in Beijing, from 500-1000 beds large municipal hospitals (Grade III) to 200-500 beds district level hospital (Grade II). Approximately 3,000 new cases of breast cancer are diagnosed and treated in grade II and III hospitals each year in Beijing. To evaluate the current clinical practice in breast cancer, we obtained all medical information on the time of first visit hospital, stepwise examinations, different surgical treatment or chemotherapy or immunotherapy from 3,473 newly diagnosed breast cancers in Beijing, 2008.

MATERIALS AND METHODS**Study Population**

According to the data from Beijing Cancer Registry, 3473 Beijing citizens were diagnosed as primary breast cancer and received anti-cancer therapy from January 1 to December 31, 2008. In this study, 101 hospitals provided the basic and clinical data of these patients.

Received 2010-11-15; Accepted 2011-01-12

This work was supported by the grant from Beijing Municipal Science & Technology Commission (No. D09050703650902).

*Contributed equally to this study.

**Corresponding author.

E-mail: zhangl@mail@yahoo.com.cn

Table 1. The general information of breast cancer patients in Beijing, 2008

Information	Number of patients	%
Sex		
Male	13	0.37
Female	3460	99.63
Marital status		
Unmarried	51	1.47
Married	3353	96.54
Divorced or widowed	51	1.47
Unknown	18	0.52
Menstrual status*		
Premenopausal	1991	57.54
Postmenopausal	1442	41.68
Unknown	27	0.78
Diseases history		
History of benign breast disease	254	7.31
Personal cancer history	133	3.83
Family history of breast cancer	495	14.25
Family history of cancer	166	4.78
Total	3473	

* Excluded 13 cases of male breast cancer

Data Collection

A questionnaire was approved by the panel of the breast cancer experts including epidemiologists and breast surgeons, and used in this study from March 1 to August 1, 2010. The data of the breast cancer patients were collected mainly from the inpatient medical records and partly from the outpatient medical records, and then filled in the questionnaire forms by trained surveyors from the medical record rooms of 101 hospitals in Beijing. If the patient was diagnosed and treated in more than one hospital, we adopt the data from the hospital where the patient received surgical treatment. Some information of outpatient treatment was collected through telephone interviews.

Evaluation Criteria

The strategies that met the criteria of (NCCN Clinical Practice Guidelines in Oncology) and the recommendation of 2007 St Gallen conference^[2,3], as well as advice of breast cancer experts in Beijing, were defined as standard diagnostic and therapeutic methods.

Quality Control

The survey questionnaire design, training of surveyors, data review, data collection and data analysis were all well-controlled. During peer review, the filled questionnaire forms were double-checked first by two surveyor and then re-checked by the monitor randomly. All the data were finally input using parallel double-entry method and checked with ACCESS 2003 version.

Statistical Analysis

The frequency and proportions of all collected variables were calculated using statistical software SPSS 13.0.




Figure 1. The age distribution of breast cancer patients in Beijing, 2008.

RESULTS

Characteristics General Date of the Patients

Among all 3473 patients, 3460 were females and 13 were males, with an average age of 54.4±12.1 years (range 20-92 years). The demographic characteristics of the patients are presented in Table 1. The age distribution of the patients in this study is shown in Figure 1.

The clinical tumor size was evaluated based primarily on ultrasonic or mammography record and secondarily on the document physical examination, 46.96% of the patients had tumors ≤2 cm. The pathological tumor size was defined according to the pathology report, and tumors ≤1 cm and 1-2 cm were 12.64% and 31.62%, respectively. 23.90% of the patients had no pathological document for tumor size. 36.14% of the patients had pathologically confirmed lymph node metastasis. 80.77% of the patients were invasive ductal carcinoma (Table 2).

Of all the cases, 3229 had document of estrogen receptor (ER) and/or progesterone receptor (PR), 72.30% of all the cases were ER and/or PR positive, 19.38% were ER and PR negative and 1.30% were uncertain, respectively. 3164 cases had document of Her-2 status, 476 (13.71%) were positive and 332 (9.56%) had uncertain status.

Detection and Diagnosis

Among 3473 patients, 2851 (82.09%) were symptomatic with the median time interval of one month from the initial self-awareness of the symptoms to visiting doctors. 17.33% of the cases were detected during regular physical examinations, and 30.07% of them were detected by image examination. The details of detection were listed in Table 3.

All 99.77% of the patients were treated based on pathological diagnosis. Among them, 19.02% were diagnosed using fine needle aspiration biopsy (FNAB), 34.11% were diagnosed using core needle biopsy (CNB), and 46.87% were diagnosed through fresh frozen section biopsy. The rates of sentinel lymph node biopsy (SLNB) and ultrasound guide FNAB ultras graphic abnormal axillary node were 15.92% and 6.10%, respectively (Table 3). There were 685 (19.72%) cases having the pathological information of axillary node before treatment.

In our study, 31.6% of the patients with positive ER status received semi-qualitative detection, and 30.2% of the patients with PR positive status received semi-qualitative detection.

Table 2. The clinical and pathological characters of breast cancer in Beijing, 2008 (n=3473)

	Number of cases	%
Clinical character		
Tumor size (cm)		
≤2	1631	46.96
2-5	1491	42.93
>5	128	3.69
T4	126	3.63
Not accessed	97	2.79
Pathological review		
Tumor size (cm)		
≤1	439	12.64
1-2	1098	31.62
2-5	994	28.62
>5	112	3.22
Not assessed	830	23.90
Lymph node metastasis		
No	1953	56.23
Yes	1255	36.14
Not assessed	265	7.63
Histological type		
Carcinoma in situ	160	4.61
Invasive ductal carcinoma	2805	80.77
Invasive lobular carcinoma	165	4.75
Mucinous carcinoma	108	3.11
Other histological types	214	6.16
Without pathological diagnosis	21	0.60
ER/PR		
+	2511	72.30
-	673	19.38
±	45	1.30
No test	244	7.03
Her-2		
+	476	13.71
-	2356	67.84
Uncertain	332	9.56
No test	309	8.90
Total	3473	

Treatment

Among 3374 (97.15%) patients who received surgical therapy, 74.13% received mastectomy without breast reconstruction, 1.60% received mastectomy with reconstruction and 24.27% received breast conserving surgery. Among 2892 cases (83.27%) who underwent axillary lymph node dissection (ALND), 1666 cases (57.61%) were lymph node negative. Among all the cases with negative pathological node, only 245 cases (12.54%) saved ALND because of negative SLN (Table 4).

Among all the 2580 cases (74.29%) who received chemotherapy, 1316 (37.89%) had endocrine therapeutic records, and 943 cases (27.15%) had the radio therapeutic records. This may be underestimated because some patients may actually be treated in outpatients of more than two hospitals or use different IDs, whose clinical information was hardly captured completely by our survey.

Table 3. The detection and diagnosis of the breast cancer in Beijing, 2008

	Number of cases	%
Detection		
Breast self-examination	2851	82.09
Nipple inspection	19	0.67
Nipple discharge	93	3.26
Palpable neoplasm	2598	91.13
Other symptoms	141	4.95
Physical examination		
Clinical breast examination	421	69.93
Image examination	181	30.07
Unknown	20	0.58
Diagnosis		
Breast lesion		
FNAB	659/3465	19.02
CNB	1182/3465	34.11
Frozen section/general pathology	1624/3465	46.87
Axillary staging		
SLNB	553	15.92
BUS guided node needle biopsy	212	6.10
Immunohistochemistry examination		
ER		
No test	243/3473	7.00
Semi-quantitative in positive	717/2269	31.60
PR		
No test	245/3473	7.05
Semi-quantitative in positive	658/2179	30.20

Table 4. The treatment in breast cancer patients in Beijing, 2008

	Number of cases	%
Treatment		
Final Surgery		
Breast	3374	97.15
Mastectomy without reconstruction	2501/3374	74.13
Mastectomy with reconstruction	54/3374	1.60
BCS	819/3374	24.27
Axillary node		
Axillary dissection	2892/3473	83.27
Negative node	1666/2892	57.61
No ALND for negative SLNB	246/1953	12.54
Radiotherapy	943/3473	27.15
Adjuvant systemic therapy	3074/3473	88.51
Chemotherapy	2580/3473	74.29
Endocrine therapy	1316/3473	
Anti-Her-2 therapy	96/476	20.17

Non-Standard Diagnosis and Treatment

Among 3473 cases, 0.6% of the breast cancer patients received clinical treatment without pathologic data. In the 160 patients with ductal carcinoma *in situ* (DCIS) 105 (65.63%) received ALND and 59 (36.88%) received chemotherapy. Of the 2580 patients received chemotherapy, 312 (12.10%) experienced chemotherapy less than 4 cycles.

Table 5. Non-standard diagnosis and treatment in breast cancer patients in Beijing, 2008

	Number of cases	%
Immunohistochemistry examination		
ER		
No test	243/3473	7.00
PR		
No test	245/3473	7.05
Her-2		
No test	309/3473	8.90
Pathological examination		
No histopathological examination	21/3473	0.60
No histopathological grading	1090/2805	38.86
No tumor size	830/3452	24.04
Peritumoral vascular invasion (unknown)	2320/3452	67.21
Lymph nodes metastasis (unknown)	265/3452	7.68
Treatment		
Surgery		
BCS without mammography	323/819	39.44
ALND	105/160	65.63
BCS without radiotherapy	212/819	25.89
Radiotherapy		
BCS without radiotherapy	316/819	38.58
After mastectomy if indicated without radiotherapy	2662/435	60.23
Chemotherapy		
DCIS with chemotherapy	59/160	36.88
<4 cycles	312/2580	12.10
Endocrine therapy		
HR-positive without endocrine therapy	819/2511	52.45
HR-negative with endocrine therapy	62/673	9.21

Among the 819 cases received BCS, 212 (25.89%) had no pathological examination of margin status following breast conservative surgery (Table 5).

The important information for treatment decision such as pathological tumor size, histological grade, the status of lymph nodes and the conditions of vascular thrombosis were missing in 24.04%, 38.86%, 7.68% and 67.21% of the patients, respectively.

The missing information of ER, PR and Her-2 status in the medical records of the breast cancer patients were 7%, 7.05% and 8.9%, respectively.

Of all the BCS patients, 316 (38.58%) and 262 (60.23%) patients had no records about radiotherapy after BCS and after mastectomy with radiotherapy indication, respectively. Among the above 578 patients without the information of radiotherapy, 350 cases were complemented through telephone interviews. It was confirmed that 93 cases (45.81%) received radiotherapy after BCS and 59 (40.14%) received radiotherapy after mastectomy. Of the patients with positive hormone-receptor (HR), 52.45% had no medical record about endocrine therapy. Among the 1692 cases without endocrine therapy, missing information of the endocrine therapy in 311 patients was complemented through

telephone interviews and among them 249 (80.06%) received endocrine therapy and 62 (19.94%) did not. On the contrary, 9.21% of the HR-negative patients received endocrine therapy.

DISCUSSION

In our study, the infiltrating ductal cancer is the major type of breast cancer in Beijing with the proportion of 80.77% and infiltrating lobular cancer followed (4.75%). This is generally consistent with the Surveillance, Epidemiology and End Results (SEER), in which infiltrating ductal and lobular cancers accounted for 83.4% and 7.4%, respectively^[4].

Among all breast cancer cases in this study, 72.30% were ER⁺ and/or PR⁺, and 19.38% were ER-/PR-, while in SEER data 79% of tumors were ER⁺ and/or PR⁺ and 21% were ER-/PR-^[5]. The Her-2 status in USA was 19% aged ≤ 49 years, and 15% aged ≥ 50 years^[6]. It is not evaluated in Beijing. The uncertain cases should be tested by FISH or CISH, however, they are not used widely in Beijing.

In terms of the tumor size, 46.96% were ≤ 2 cm in diameter and 36.14% had lymph node metastasis, while in America according to the SEER data both proportions were significantly different, which were 75.9% and 26.3%, respectively between 1992 and 2003^[7]. This reflects the notable delay of breast cancer diagnosis in Beijing that will inevitably affect the outcome negatively.

Since the 1990s, the national mammography screening was developed gradually in western countries. From New Mexico SEER files (n=5,067), the proportion of breast cancer cases detected by mammography screening was 76.8% from 1995 through 2004^[8]. However, in Beijing only 17.33% of breast cancer cases were detected during routine physical examinations including palpation of doctors, ultrasonic imaging, mammography, and 30.07% of them were detected by image examination, which in part delay the early diagnosis. This result highlighted the importance of health education in general population and screening among high-risk women for the early detection of breast cancer.

Imaging guided needle biopsy is the first choice of tissue acquiring for histopathology while only 34.11% of cases were diagnosed by CNB.

In addition, we found that in the pathology reports, important information such as tumor size, histological grade, nodal status and vascular channel invasion were missing and the missing rates ranged from 7.68% to 67.21%. However, such information is important for treatment decision^[9-15].

SLNB is the standard axillary staging procedure and negative SLNB is the indication for saving axillary dissection^[16, 17]. According to the SEER data^[18], from 1998 to 2004 the use of SLNB (\pm ALND) increased from 11% to 59% in USA. However, our study found only 15.92% (\pm ALND) received SLNB and among cases with pathological negative node, only 12.54% were diagnosed with SLNB and avoided axillary dissection.

In 1991, the NCI Consensus Conference stated that BCS was an appropriate primary therapy for the majority of females with early breast cancer. In a large population-based

study using Medicare data from 2003 to 2004, the overall use of BCS in the elderly was 81.8% and varied minimally from 74% to 84% across the United States^[19]. Japanese Breast Cancer Society reported 48.4% received BCS in 20417 cases in 2003^[20]. However, only 24.27% of breast cancer cases underwent BCS in Beijing.

Among the proved Her-2 over-expression cases (476), only 98 patients received Herceptin therapy. It may be partly due to the reason that anti-her-2 treatment for primary breast cancer is not covered by health insurance in Beijing.

Over-treatment for DCIS was found frequently in breast cancer patients of Beijing. Although in NCCN, ALND is discouraged for patients with DCIS, our data showed that this therapy still prevailed, and some patients with DCIS received chemotherapy.

On the other hand, under-treatment was notable among patients undergoing surgery especially BCS. This was best represented by no pathological examination of margin following lumpectomy and no post-operative radiation therapy.

In the aspect of endocrine therapy, 52.45% of HR-positive patients had no record about treatment with endocrine drugs, though data missing and the presence of other conditions that may prevent the prescription (e.g. complications) could not be excluded. Nevertheless, some HR-negative patients received endocrine therapy, which obviously went against the treatment guidelines.

Through this mass survey without sampling error, we investigated the current status and found many non-standard practices in the diagnosis and treatment of breast cancer in Beijing, which remain to be addressed in the future.

Some limitations of the present study should be mentioned. Based on the review of medical records, our study inevitably suffered the impact of information bias. Furthermore, we did not collect data on potential causes for the non-standard practices and this deserves further study.

REFERENCES

1. Ferlay J, Shin HR, Bray F, et al. GLOBOCAN 2008, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 10 [Internet]. Lyon: International Agency for Research on Cancer; 2010. Available from: <http://globocan.iarc.fr>.
2. National Comprehensive Cancer Network (NCCN). Breast Cancer. 2008. V2.2. Available from: http://www.nccn.org/professionals/physician_gls/pdf/breast.pdf. Accessed on June 10, 2008.
3. Goldhirsch A, Wood WC, Gelber RD, et al. Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007. *Ann Oncol* 2007; 18:1133-44.
4. Carter CL, Allen C, Henson DE. Relation of tumor size, lymph node status, and survival in 24,740 breast cancer cases. *Cancer* 1989; 63: 181-7.
5. Dunnwald LK, Rossing MA, Li CI. Hormone receptor status, tumor characteristics, and prognosis: a prospective cohort of breast cancer patients. *Breast Cancer Res* 2007; 9:R6.
6. Cronin KA, Harlan LC, Dodd KW, et al. Population-based Estimate of the prevalence of HER-2 positive breast cancer tumors for early stage patients in the US [J]. *Cancer Investigation* 2010; 28:963-8.
7. Chen SL, Hoehne FM, Giuliano AE. The Prognostic Significance of Micrometastases in breast cancer: a SEER population-based analysis. *Ann Surg Oncol* 2007; 14:3378-84.
8. Hill DA, Nibbe A, Royce ME, et al. Method of detection and breast cancer survival disparities in Hispanic women [J]. *Cancer Epidemiol Biomarkers Prev* 2010; 19:2453-60.
9. Rosen PP, Groshen S, Kinne DW, et al. Factors influencing prognosis in node-negative breast carcinoma: analysis of 767 T1N0M0/T2N0M0 patients with long-term follow-up. *J Clin Oncol* 1993; 11:2090-100.
10. Rosen PP, Groshen S, Kinne DW. Prognosis in T2N0M0 stage I breast carcinoma: a 20-year follow-up study. *J Clin Oncol* 1991; 9:1650-61.
11. Fisher ER, Anderson S, Redmond C, et al. Pathologic findings from the National Surgical Adjuvant Breast Project protocol B-06. 10-year pathologic and clinical prognostic discriminants[J]. *Cancer* 1993; 71: 2507-14.
12. Truong PT, Berthelet E, Lee J, et al. The prognostic significance of the percentage of positive/dissected axillary lymph nodes in breast cancer recurrence and survival in patients with one to three positive axillary lymph nodes. *Cancer* 2005; 103:2006-14.
13. Smith JA 3rd, Gamez-Araujo JJ, Gallager HS, et al. Carcinoma of the breast: analysis of total lymph node involvement versus level of metastasis. *Cancer* 1977; 39:527-32.
14. Lee AK, DeLellis RA, Silverman ML, et al. Prognostic significance of peritumoral lymphatic and blood vessel invasion in node-negative carcinoma of the breast. *J Clin Oncol* 1990; 8:1457-65.
15. Bettelheim R, Penman HG, Thornton-Jones H, et al. Prognostic significance of peritumoral vascular invasion in breast cancer. *Br J Cancer* 1984; 50:771-7.
16. Veronesi U, Galimberti V, Mariani L, et al. Sentinel node biopsy in breast cancer: early results in 953 patients with negative sentinel node biopsy and no axillary dissection. *Eur J Cancer* 2005; 41:231-7.
17. Naik AM, Fey J, Gemignani M, et al. The risk of axillary relapse after sentinel lymph node biopsy for breast cancer is comparable with that of axillary lymph node dissection: a follow-up study of 4008 procedures. *Ann Surg* 2004; 240:462-71.
18. Rescigno J, Zampell JC, Axelrod D. Patterns of axillary surgical care for breast cancer in the era of sentinel lymph node biopsy. *Ann Surg Oncol* 2009; 16:687-96.
19. Alderman AK, Bynum J, Sutherland J, et al. Surgical treatment of breast cancer among the elderly in the United States. *Cancer* 2010; [Epub ahead of print].
20. Japanese Breast Cancer Society. Results of questionnaires concerning breast cancer surgery in Japan 1980-2003. *Breast Cancer*. 2005; 12:1-2.